Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 5, 2012, Pages 805-812

  Chen, Yi Bin ^a   Aldridge, Julie ^b   Kim, Haesook T ^b   Ballen, Karen K ^a   Cutler, Corey ^b   Kao, Grace ^b   Liney, Deborah ^b   Bourdeau, Greg ^b   Alyea, Edwin P ^b   Armand, Philippe ^b   Koreth, John ^b   Ritz, Jerome ^b   Spitzer, Thomas R ^a   Soiffer, Robert J ^b   Antin, Joseph H ^b   Ho, Vincent T ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

RIC; Umbilical cord blood transplantation

Indexed keywords

ANTIVIRUS AGENT; BORTEZOMIB; BUSULFAN; CYCLOSPORIN; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HERPES ZOSTER; HLA MATCHING; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MORTALITY; OVERALL SURVIVAL; PNEUMOCYSTOSIS; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; UMBILICAL CORD BLOOD; UNRELATED DONORS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; UNRELATED DONORS; YOUNG ADULT;

EID: 84859817674     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.016     Document Type: Article

References (26)

1. Laughlin M.J., Barker J., Bambach B., et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001, 344:1815-1822.
2. Wagner J.E., Gluckman E. Umbilical cord blood transplantation: the first 20 years. Semin Hematol 2010, 47:3-12.
3. Eapen M., Rocha V., Sanz G., et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010, 11:653-660.
4. Brunstein C.G., Gutman J.A., Weisdorf D.J., et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010, 116:4693-4699.
5. Ballen K.K., Spitzer T.R., Yeap B.Y., et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant 2007, 13:82-89.
6. Barker J.N., Weisdorf D.J., DeFor T.E., et al. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 2003, 102:1915-1919.
7. Brunstein C.G., Barker J.N., Weisdorf D.J., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007, 110:3064-3070.
8. Cutler C., Stevenson K., Kim H.T., et al. Double umbilical cord blood transplantation with reduced-intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant 2011, 46:659-667.
9. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
10. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
11. Gray R. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
12. Fine J., Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
13. Ho V.T., Kim H.T., Aldridge J., et al. Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:1196-1204.
14. Rosenbaum P.R., Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70:41-55.
15. Ballen K.K., Cutler C., Yeap B.Y., et al. Donor-derived second hematologic malignancies after cord blood transplantation. Biol Blood Marrow Transplant 2010, 16:1025-1031.
16. Brunstein C.G., Eapen M., Ahn K., et al. Reduced-intensity conditioning (RIC) transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes [abstract]. Blood 2010, 116:908.
17. Majhail N., Brunstein C.G., Warlick E.D., et al. Reduced-intensity allogeneic hematopoietic cell transplantation in older patients with acute myeloid leukemia and myelodysplastic syndromes: comparable outcomes with unrelated umbilical cord blood and HLA-identical sibling donors [abstract 112]. Biol Blood Marrow Transplant 2011, 17:S155.
18. Ponce D.M., Zheng J., Gonzales A., et al. Reduced late mortality risk contributes to similar survival after double unit cord blood transplantation as compared with related and unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:1316-1326.
19. Verneris M.R., Brunstein C.G., Barker J., et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009, 114:4293-4299.
20. Dey B.R., McAfee S., Colby C., et al. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2005, 128:351-359.
21. Levy M., Symons H., Fuchs E. Clinical tumor responses despite graft rejection after nonmyeloablative conditioning and transplantation of partially HLA-mismatched (haploidentical) bone marrow [abstract]. Blood 2005, 106:2897.
22. Jacobson C.A., Turki A.T., McDonough S.M., et al. Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2011, epub.
23. Brunstein C.G., Weisdorf D.J., DeFor T., et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006, 108:2874-2880.
24. Blaes A.H., Cao Q., Wagner J.E., et al. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant 2010, 16:287-291.
25. Barker J.N., Doubrovina E., Sauter C., et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010, 116:5045-5049.
26. Heslop H.E., Slobod K.S., Pule M.A., et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010, 115:925-935.